Ir-UA

Ir-UA is an usnic acid-derived iridium (III) complex that enhances PD-L1 expression and converts "cold tumors" into "hot tumors." Ir-UA stimulates PD-L1 expression by explicitly regulating the PD-L1 transcription factor[1].

Product Specifications

CAS Number

[3033235-42-3]

UNSPSC

12352211

Target

PD-1/PD-L1

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ir-ua.html

Solubility

10 mM in DMSO

Smiles

OC1=C(C(O)=C2C(C)(C(OC2=C1C(C)=O)=CC/3=O)C(C3=C(C)\NCC4=CC=[N](C(C5=[N]6C=CC(C)=C5)=C4)[Ir+3]786(C9=CC=CC=C9C%10=[N]8C=CC=C%10)[N]%11=CC=CC=C%11C%12=CC=CC=C%127)=O)C.[F-][P+5]([F-])([F-])([F-])([F-])[F-]

Molecular Formula

C52H43F6IrN5O6P 2+

Molecular Weight

1171.11

References & Citations

[1]Deng D, et al. Iridium (III) -Based PD-L1 Agonist Regulates p62 and ATF3 for Enhanced Cancer Immunotherapy. J Med Chem. 2024 Apr 25;67 (8) :6810-6821.